Anti-Sar-Cov-2 Spike Protein Antibody For Immunofluorescence

Lab Reagents

Human IgG antibody Laboratories manufactures the anti-sar-cov-2 spike protein antibody for immunofluorescence reagents distributed by Genprice. The Anti-Sar-Cov-2 Spike Protein Antibody For Immunofluorescence reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Antibody. Other Anti-Sar-Cov-2 products are available in stock. Specificity: Anti-Sar-Cov-2 Category: Spike Group: Protein Antibody

Protein Antibody information

Anti-Spike S1 Antibody (SARS-CoV-2)

100715-1 20 µg
EUR 300
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial

E80028-2 100 ul
EUR 860.2

Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2)

100684-2 50 µg
EUR 435
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)

100696-2 1 mg
EUR 3200
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Spike Trimer (S1+S2), His-tag (SARS-CoV-2)

100728-2 1 mg
EUR 2995
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa.

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)

78028-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.
The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (eGFP Reporter)

78035-2 500 µl x 2
EUR 5145
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.

The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag

E80021-2 1 ml
EUR 4276.8

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag

E80023-2 1 ml
EUR 3934.7

Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2)

100698-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 cell expression system. MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Avi-His-tag (SARS-CoV-2)

100730-2 1 mg
EUR 2720
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685 with a C-terminal Avi-His-tag, expressed in a HEK293 expression system, MW=78 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2)

100769-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2)

100846-2 1 mg
EUR 2600
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2)

100992-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. 

Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)

78112-2 500 µl x 2
EUR 4405
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)

78637-2 500 µl x 2
EUR 3995
Description: The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3.The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices.

Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)

79982-2 500 µl x 2
EUR 8110
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_
The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_